Healthy Returns: FDA chief Marty Makary on compounded GLP-1s, vaccines and China
Makary helms the FDA in the midst of a contentious stretch for the agency, defined by massive staff and budget cuts and sweeping changes to vaccine policy.
Fiscal Year: January - December
Eli Lilly and Company (LLY), listed on the NYSE, has a market capitalization of $. As of Feb 21, 2026, the stock is trading at $1,009.52 per share, offering investors a clear view of its current market value. Eli Lilly and Company is a prominent player in the industry sector, attracting both institutional and retail investors due to its performance and potential.
With a P/E ratio of 43.99, investors can assess the stock's valuation in comparison to its earnings. A P/E ratio is a crucial indicator for value investors, showing whether the stock is over or undervalued relative to its current earnings. Eli Lilly and Company also offers a dividend yield of 0.69%, making it an attractive option for income-focused investors who seek regular dividends.
Our Discounted Cash Flow (DCF) analysis reveals that Eli Lilly and Company (LLY) may be overvalued compared to its intrinsic worth. However, to see the exact DCF fair value, please Login or Upgrade for access.
The proprietary SS Score for Eli Lilly and Company is a unique metric that analyzes the company's financial health and growth potential. The score takes into account critical factors such as revenue growth, net income, free cash flow (FCF) compound annual growth rate (CAGR), the trend of shares outstanding, and the debt-to-FCF ratio. This helps investors to make a more informed decision, as an undervalued stock might still have poor financial fundamentals.
To view the detailed SS Score for Eli Lilly and Company, Login or Upgrade for access.
The Price to Free Cash Flow (P/FCF) ratio for Eli Lilly and Company is 100.52, offering insights into how much investors are paying for the company's free cash flow. A lower P/FCF ratio typically suggests that the stock is undervalued, while a higher ratio may indicate overvaluation.
In summary, Eli Lilly and Company (LLY) has shown consistent financial performance, as illustrated by the financial charts above, which track its revenue growth, net income, free cash flow, and shares outstanding over the past several years. These metrics provide investors with key insights into the company's past and projected future performance. Investors should use the SS Score alongside the DCF Fair Value to make better-informed decisions about whether to buy or hold the stock.
*This analysis is for informational purposes only and does not constitute investment advice. Always read the company's 10-K filings and do your own research before making any investment decisions.
Whether Eli Lilly and Company (LLY) is a good stock to buy depends on various factors, including its financial health, market conditions, and your investment strategy. Our analysis indicates that the stock may be overvalued compared to its intrinsic value. However, it is important to assess the SS Score and review the company's fundamentals before making any investment decisions.
The fair value of Eli Lilly and Company (LLY) is determined through our Discounted Cash Flow (DCF) analysis. This value represents the intrinsic worth of the stock based on its expected future cash flows. To view the specific fair value, consider subscribing to our service for complete access.
The SS Score is a proprietary financial quality metric that assesses factors such as revenue growth, net income, free cash flow growth, and debt levels. It helps investors evaluate the overall financial health of Eli Lilly and Company. To access the full SS Score, consider upgrading your subscription.
Eli Lilly and Company is a significant player in the industry sector, with a market capitalization of $ and a competitive P/E ratio of 43.99. Investors should compare these metrics with industry peers to gauge whether Eli Lilly and Company is outperforming or underperforming within its sector.
Makary helms the FDA in the midst of a contentious stretch for the agency, defined by massive staff and budget cuts and sweeping changes to vaccine policy.
Landmark VIVID-2 data showed more than 90% of patients who achieved steroid-free remission at one year maintained steroid-free control through three years Additional new data revealed exceptionally l...
Australia's CSL said on Wednesday it had entered into an exclusive licensing agreement with Eli Lilly and Co , granting it certain rights to develop and commercialise clazakizumab, an antibody aimed a...
ALAMEDA, Calif.--(BUSINESS WIRE)-- #CRISPR--Scribe Therapeutics achieves second success milestone for in vivo program in collaboration with Eli Lilly and Company.
Mounjaro-maker Eli Lilly wants to turn India into a hub for its global supply chain, a senior executive at the U.S. drugmaker said, as part of its previously committed $1 billion investment to contrac...
Eli Lilly is included due to its strategic positioning with respect to sustainability opportunities, specifically in HealthCare Access and Innovation. Advanced Micro Devices is owned for its exception...
INDIANAPOLIS, Feb. 16, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) will participate in TD Cowen's 46th Annual Health Care Conference on March 2, 2026. Lucas Montarce, executive vice presiden...
Selpercatinib demonstrated a highly statistically significant and clinically meaningful improvement in reducing the risk of disease recurrence or death Results from the LIBRETTO-432 trial build on pr...
Following record-breaking adoption of its GLP-1 portfolio and positive Phase 3 data in Alzheimer's treatments, LLY has entered a new growth tier. Our multi-factor analysis suggests now is an opportune...
Pharma earnings weren't the main focus for drugmakers this quarter. "2025 was about understanding kind of the rules of the future of the game," McKinsey Senior Partner Greg Graves told CNBC.
Eli Lilly had $1.5 billion worth of pre-launch inventory of its experimental oral weight-loss drug, a filing showed on Thursday, ahead of an expected decision by the U.S. Food and Drug Administration ...
SpaceX is generating significant value with the rapid expansion of its Starlink broadband service. Eli Lilly shares contributed to performance as Zepbound continues to gain share for the treatment of ...
Eli Lilly stock (NYSE: LLY) has been on a tear, surging over 60% in just the last six months. This momentum is part of a broader pattern of explosive growth; the stock has repeatedly rallied more than...
Eli Lilly has won Chinese regulators' approval for its drug to treat chronic inflammatory bowel disease, expanding the treatment's use to the world's second-largest pharmaceutical market, it said on W...
The strategic move is seen as a significant step in enhancing Lilly's capabilities in genetic medicine, adding pressure as broader markets edged lower.
Eli Lilly has struck a deal to buy genetic-medicine biotechnology company Orna Therapeutics for up to $2.4 billion in cash.
Lilly agrees to acquire Orna Therapeutics in an all-cash deal.
Eli Lilly will acquire therapy developer Orna Therapeutics for up to $2.4 billion in cash, the companies said on Monday.
Orna's in vivo CAR-T pipeline includes potential best-in-class programs to reset the immune system and address B cell-driven autoimmune diseases Acquisition provides a broad platform for long-term inn...
Chinese drugmaker Innovent Biologics and Eli Lilly plan to target cancer and immune system diseases under the partnership.
China's Innovent Biologics has struck a new deal with Eli Lilly to develop immunology and oncology drugs, under which the U.S. drugmaker will pay $350 million upfront and as much as $8.5 billion more ...
Novo Nordisk (NVO) is down 40% year-over-year while Eli Lilly (LLY) is up 30%. It's a shake-up in the GLP-1 trade that few expected, especially with Matt Maley pointing out that Novo Nordisk originall...
Companies looking to sell weight-loss drugs directly to consumers, including Novo Nordisk's Wegovy, will shell out millions of dollars for celebrity-filled ads during Sunday's Super Bowl with its prom...
Eli Lilly and Company's price jump following its latest earnings release is completely justified going by both the performance and guidance. Both LLY revenue and EPS growth exceeded guidance, despite ...
Novo Nordisk and Eli Lilly are facing an uncomfortable new price point this week after a $49 weight-loss pill jolted the GLP-1 market. By launching a low-cost, compounded oral version of semaglutide, ...
Below estimates were sourced from SimplyWallSt and are intended for educational purposes only as a baseline for the analysis.
| Year | FCF Estimate | % | # Analysts |
|---|---|---|---|
| 2026 | 18.53B | Analyst x5 | |
| 2027 | 28.04B | 51.27% | Analyst x6 |
| 2028 | 34.82B | 24.20% | Analyst x6 |
| 2029 | 41.67B | 19.64% | Analyst x5 |
| 2030 | 47.69B | 14.45% | Analyst x5 |
| 2031 | 51.16B | 7.28% | Est @7.3% |
| 2032 | 54.16B | 5.87% | Est @5.9% |
| 2033 | 56.80B | 4.88% | Est @4.9% |
| 2034 | 59.02B | 3.90% | Est @3.9% |
| 2035 | 61.05B | 3.44% | Est @3.4% |
Below are the FCF estimates with the discount factor and the calculated present value with the terminal value that led the results above.
| Year | FCF | Discount Factor | PV of Future FCF |
|---|---|---|---|
| 2024A | 3.76B | 1.00 | 3.76B |
| 2025A | 8.97B | 1.00 | 8.97B |
| 2026E | 18.53B | 1.08 | 17.22B |
| 2027E | 28.04B | 1.16 | 24.19B |
| 2028E | 34.82B | 1.25 | 27.90B |
| 2029E | 41.67B | 1.34 | 31.01B |
| 2030E | 47.69B | 1.45 | 32.96B |
| 2031E | 51.16B | 1.56 | 32.85B |
| 2032E | 54.16B | 1.68 | 32.30B |
| 2033E | 56.80B | 1.81 | 31.46B |
| 2034E | 59.02B | 1.94 | 30.36B |
| 2035E | 61.05B | 2.09 | 29.17B |
| Terminal | 1.21T | 2.09 | 578.85B |
The information given by Studying Stocks and provided in the web and/or mobile applications (Platforms) is only factual information and should not be considered financial advice.
Any information contained in this website has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.
When creating an account, you acknowledge that you are:
We retain the right to cancel your account for any reason, or refuse your account creation request.
The information on our Platforms is not comprehensive and is intended to provide a summary of the subject matter covered. While we use all reasonable attempts to ensure the accuracy and completeness of the data and information on our Platforms, to the extent permitted by law, we make no warranty regarding the information on these Platforms. You should monitor any changes to the information contained on these Platforms.
Furthermore we make no commitments in regards to the minimum amount of uptime that our platforms will maintain, although we will make ever reasonable attempt to ensure that the platforms are operational. Therefore, any reference of "latest", "current" and related words about the financial data presented here may not be up to date with the financial markets or represent reality of the information.
We are not liable to you or anyone else if interference with or damage to your computer systems occurs in connection with the use of these Platforms or a linked website. You must take your own precautions to ensure that whatever you select for your use from our Platforms is free of viruses or anything else (such as worms or Trojan horses) that may interfere with or damage the operations of your computer systems.
We may, from time to time and without notice, change or add to the Platforms (including the Terms) or the information, products or services described in it. However, we do not undertake to keep the Platforms updated. We are not liable to you or anyone else if errors occur in the information or the Platforms is not up-to-date.
Our Platforms may contain links to websites operated by third parties. Those links are provided for convenience and may not remain current or be maintained. Unless expressly stated otherwise, we do not endorse and are not responsible for the content on those linked websites and have no control over or rights in those linked websites.
These Platforms are for your personal, non-commercial use only. You may not modify, copy, distribute, transmit, display, perform, reproduce, publish, license, commercially exploit, create derivative works from, transfer, or sell any Content, software, products or services contained within these Platforms. You may not use these Platforms, or any of its Content, to further any commercial purpose, including any advertising or advertising revenue generation activity on your own website.
You must not do any act that we would deem to be inappropriate, is unlawful or is prohibited by any laws applicable to these Platforms, including but not limited to:
If we allow you to post any information to our Platforms, we have the right to take down this information at our sole discretion and without notice.
To the maximum extent permitted by law, we make no warranties or representations about these Platforms or the Content, including but not limited to warranties or representations that they will be complete, accurate or up-to-date, that access will be uninterrupted or error-free or free from viruses, or that these Platforms will be secure.
We reserve the right to restrict, suspend or terminate without notice your access to these Platforms, any Content, or any feature of these Platforms at any time without notice and we will not be responsible for any loss, cost, damage or liability that may arise as a result.
To the maximum extent permitted by law, in no event shall we be liable for any direct and indirect loss, damage or expense – irrespective of the manner in which it occurs – which may be suffered due to your use of our Platforms and/or the information or materials contained on it, or as a result of the inaccessibility of these Platforms and/or the fact that certain information or materials contained on it are incorrect, incomplete or not up-to-date.
This website utilises cookies. If you do not have cookies enabled in your web browser some functions of the site may not work as intended.